Litcius/Paper detail

Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients

Luis García de Guadiana‐Romualdo, Mónica Martínez Martínez, María Dolores Rodríguez Mulero, Patricia Esteban-Torrella, Marta Hernández Olivo, María José Alcaraz García, Valerio Campos‐Rodríguez, Natalia Sancho‐Rodríguez, María Galindo Martínez, Antonia Alcaraz, María Salomé Ros Braquehais, Carlos Báguena, Verónica Ramos Arenas, Cristina Tomás Jiménez, Luciano Consuegra‐Sánchez, Andrés Conesa-Hernandez, Pascual Piñera, Enrique Bernal

2021International Journal of Infectious Diseases42 citationsDOIOpen Access PDF

Abstract

OBJECTIVES: Thromboinflammation, resulting from a complex interaction between thrombocytopathy, coagulopathy, and endotheliopathy, contributes to increased mortality in COVID-19 patients. MR-proADM, as a surrogate of adrenomedullin system disruption, leading to endothelial damage, has been reported as a promising biomarker for short-term prognosis. We evaluated the role of MR-proADM in the mid-term mortality in COVID-19 patients. METHODS: A prospective, observational study enrolling COVID-19 patients from August to October 2020. A blood sample for laboratory test analysis was drawn on arrival in the emergency department. The primary endpoint was 90-day mortality. The area under the curve (AUC) and Cox regression analyses were used to assess discriminatory ability and association with the endpoint. RESULTS: A total of 359 patients were enrolled, and the 90-day mortality rate was 8.9%. ROC AUC for MR-proADM predicting 90-day mortality was 0.832. An optimal cutoff of 0.80 nmol/L showed a sensitivity of 96.9% and a specificity of 58.4%, with a negative predictive value of 99.5%. Circulating MR-proADM levels (inverse transformed), after adjusting by a propensity score including eleven potential confounders, were an independent predictor of 90-day mortality (HR: 0.162 [95% CI: 0.043-0.480]) CONCLUSIONS: Our data confirm that MR-proADM has a role in the mid-term prognosis of COVID-19 patients and might assist physicians with risk stratification.

Topics & Concepts

MedicineInternal medicineConfoundingProportional hazards modelProspective cohort studyEndothelial dysfunctionClinical endpointSurrogate endpointBiomarkerClinical trialBiochemistryChemistryCOVID-19 Clinical Research StudiesSepsis Diagnosis and TreatmentPlatelet Disorders and Treatments